Piramal Pharma Shares Surge 3% After Reaffirming FY26 Guidance

• Piramal Pharma shares recovered from early lows, surging 3% after the company reaffirmed its FY26 guidance.
• Despite a weak Q3FY26 performance with a net loss of ₹136.2 crore and revenue decline, the company maintains a positive long-term outlook.
• The company expects the March quarter to be its strongest, continuing historical trends.
• Segment-wise, CDMO revenue declined 9%, hospital generics grew 2%, and consumer healthcare saw a strong 20% growth.
• Performance was impacted by inventory destocking, slower early-stage order inflows, and regulatory delays, but recovery signs are noted since October 2025.

Why It Matters: Piramal Pharma shares rebounded as the company reaffirmed its FY26 guidance despite recent weak results.